Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (H-share abbreviation: Kelun-Biotech) reported no changes in authorised, registered or issued share capital for the month ended 31 March 2026.

• Authorised/registered capital remained unchanged at 233.19 million shares with a par value of RMB1.00 each, comprising:  – 162.77 million H shares listed in Hong Kong  – 65.77 million domestic shares  – 4.64 million unlisted foreign shares

• Issued share capital mirrored the authorised totals, and no treasury shares were held at month-end.

• Public float for the H-share class met the minimum 22.09 % requirement under Main Board Rule 13.32B, confirming sufficient market liquidity.

• There were no movements involving share options, warrants, convertibles, or other equity instruments during the month.

Joint Company Secretary Zhou Zejian submitted the return on 9 April 2026, confirming compliance with all applicable listing rules and regulatory requirements.